CD8A and myeloid sarcoma: Although MS-OCR patients had a smaller CD8+ Tcm population compared to HC before vaccination and upon second vaccination, substantial stronger quality of the CD8+ Tcm cell recall response in OCR-treated MS patients was observed compared to those of SARS-CoV-2 experienced HCs following first vaccination.